Dec. 7 , 2007 - Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its oral insulin product candidate. Several formulations using Cobalamin, which is based upon the body's natural absorption of vitamin B12 in the gastrointestinal tract, were tested in an animal model of diabetes. Additional pre-clinical studies are planned... [PDF] Access Pharmaceuticals' Press Release -Thursday, December 27, 2007
Access Pharmaceuticals, Reduce Glucose Levels in Pre-clinical Testing of Cobalamin Oral Insulin
Dec. 7 , 2007 - Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its oral insulin product candidate. Several formulations using Cobalamin, which is based upon the body's natural absorption of vitamin B12 in the gastrointestinal tract, were tested in an animal model of diabetes. Additional pre-clinical studies are planned... [PDF] Access Pharmaceuticals' Press Release -
